Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554318 | 0.87 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL636060 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4595183 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7509255 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18588914 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16674630 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3547295 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2410317 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL637167 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16510371 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | claimed |
| CN-113166079-A | Redox active compounds and their use | 克姆布鲁项目公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3837246-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBlu Projekt AG (DE) | 2021-06-23 | — | — | EP | claimed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | claimed |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU ENERGY AG (DE) | 2025-08-21 | — | — | US | disclosed |
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJECKT AG (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2021-08-19 | — | — | US | disclosed |
| CN-113166079-A | Redox active compounds and their use | 克姆布鲁项目公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3837246-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBlu Projekt AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035548-A2 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJEKT AG (DE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | CHRNB2 4381/4885CHRNA4 4537/4885CHRNB4 3824/4885 |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | CHRNB2 4381/4885CHRNA4 4537/4885CHRNB4 3824/4885 |
| US-11731945-B2 | Redox-active compounds and uses thereof | NOX4, NQO1, GPX1 | CHRNB2 4381/4885CHRNA4 4537/4885CHRNB4 3824/4885 |
| US-20210253540-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | CHRNB2 4381/4885CHRNA4 4537/4885CHRNB4 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.